GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » R1 RCM Inc (NAS:RCM) » Definitions » Sloan Ratio %

RCM (R1 RCM) Sloan Ratio % : 7.43% (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is R1 RCM Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

R1 RCM's Sloan Ratio for the quarter that ended in Sep. 2024 was 7.43%.

As of Sep. 2024, R1 RCM has a Sloan Ratio of 7.43%, indicating the company is in the safe zone and there is no funny business with accruals.


R1 RCM Sloan Ratio % Historical Data

The historical data trend for R1 RCM's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

R1 RCM Sloan Ratio % Chart

R1 RCM Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.40 14.33 11.33 17.50 -4.72

R1 RCM Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.62 -4.72 7.08 7.42 7.43

Competitive Comparison of R1 RCM's Sloan Ratio %

For the Health Information Services subindustry, R1 RCM's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


R1 RCM's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, R1 RCM's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where R1 RCM's Sloan Ratio % falls into.



R1 RCM Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

R1 RCM's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(3.3-340.1
--102.8)/4960.2
=-4.72%

R1 RCM's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-61.2-291.4
--779.9)/5749.3
=7.43%

R1 RCM's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was 1.4 (Dec. 2023 ) + -35.1 (Mar. 2024 ) + -7.6 (Jun. 2024 ) + -19.9 (Sep. 2024 ) = $-61 Mil.
R1 RCM's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 118.8 (Dec. 2023 ) + 46.7 (Mar. 2024 ) + 36.8 (Jun. 2024 ) + 89.1 (Sep. 2024 ) = $291 Mil.
R1 RCM's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -27.2 (Dec. 2023 ) + -698.4 (Mar. 2024 ) + -26.4 (Jun. 2024 ) + -27.9 (Sep. 2024 ) = $-780 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


R1 RCM  (NAS:RCM) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, R1 RCM has a Sloan Ratio of 7.43%, indicating the company is in the safe zone and there is no funny business with accruals.


R1 RCM Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of R1 RCM's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


R1 RCM Business Description

Traded in Other Exchanges
N/A
Address
434 West Ascension Way, 6th Floor, Murray, UT, USA, 84123
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received.
Executives
Tcp-asc Achi Series Lllp director, 10 percent owner 65 E 55TH ST 27TH FLOOR, TOWERBROOK CAPITAL PARTNERS L.P., NEW YORK NY 10022
John M. Sparby officer: See Remarks C/O R1 RCM INC., 401 N. MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Dominic Nakis director 433 W ASCENSION WAY, SUITE 200, MURRAY UT 84123
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Evans Richard B. Jr. officer: Principal Accounting Officer C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Lee Rivas officer: President C/O R1 RCM INC., 434 W. ASCENSION WAY, 6TH FLOOR, MURRAY UT 84123
Kyle Hicok officer: Chief Commercial Officer 434 W. ASCENSION WAY, 6TH FLOOR, MURRAY UT 84123
Jennifer D. Williams officer: Chief Financial Officer 434 W. ASCENSION WAY, 6TH FLOOR, MURRAY UT 84123
Janie Wade director C/O R1 RCM INC., 434 W. ASCENSION WAY, 6TH FLOOR, MURRAY UT 84123
Joseph Gerard Flanagan director, officer: Chief Executive Officer C/O NORTEL NETWORKS CORPORATION, 195 THE WEST MALL, TORONTO A6 M9C 5K1
Brian K. Dean director R1 RCM INC., 434 W. ASCENSION WAY, 6TH FLOOR, MURRAY UT 84123
Gary Steven Long officer: See Remarks 7050 BRIXTON PLACE, SUWANEE GA 30024
Michael C. Feiner director 1166 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Bradford Kyle Armbrester director 311 ARSENAL STREET, WATERTOWN MA 02472
Matthew S. Holt director C/O NEW MOUNTAIN CAPITAL, LLC, 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019